Conference Coverage

VIDEO: Long-term PARTNER 1 data tip scales toward TAVR


 

AT ACC 15

References

SAN DIEGO – The 5-year results of the PARTNER 1 trial in presented at the annual meeting of the American College of Cardiology were reassuring for clinicians treating patients with severe aortic stenosis at high risk for surgery, said to Dr. Jeffrey J. Popma of Beth Israel DeaconessMedical Center, Boston, in a video interview. The data showed comparable mortality between transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR), as well as long-term durability of the SAPIEN transcatheter valve, he said.

With these similar outcome results, Dr. Popma asks, can the less-invasive TAVR procedure be considered the preferred treatment over SAVR in these very-sick patients?

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

chackett@frontlinemedcom.com

Recommended Reading

CT scans comparable to functional testing for CAD
MDedge Family Medicine
VIDEO: Growing evidence supports prolonged DAPT for ACS
MDedge Family Medicine
MI survivors face higher cancer risk
MDedge Family Medicine
Five-year PARTNER 1 results held up
MDedge Family Medicine
Long-term DAPT offers ongoing post-MI benefit
MDedge Family Medicine
Evolocumab halved cardiovascular events in OSLER study
MDedge Family Medicine
Cardiovascular event rates similar in PCI and CABG after 5 years
MDedge Family Medicine
Guideline recommends combination therapy for smoking cessation in cancer patients
MDedge Family Medicine
Apple’s ResearchKit
MDedge Family Medicine
Novel Watchman device approved as warfarin alternative in atrial fib
MDedge Family Medicine